KCM
CTMX icon

Kennedy Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Kennedy Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-81,196
Closed -$623K – 670
2020
Q1 		$623K Buy
81,196
+11,457
+16% +$79.9K 0.02% 600
2019
Q4 		$580K Sell
69,739
-670
-1% -$4.52K 0.01% 649
2019
Q3 		$520K Sell
70,409
-5,098
-7% -$50.3K 0.01% 635
2019
Q2 		$847K Buy
+75,507
New +$792K 0.02% 620

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Kennedy Capital Management's CTMX Position: Q2 2020 in Review

Kennedy Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2020, closing a stake of 81,196 shares — an estimated $623K sold.

Kennedy Capital Management first reported a position in CTMX in Q2 2019 and held it in 4 quarters. The position peaked at $847K in Q2 2019. 134 funds tracked by Wall St. Rank hold CTMX as of Q2 2020.

  • Kennedy Capital Management reported no remaining CytomX Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Kennedy Capital Management sold 81,196 CytomX Therapeutics shares in Q2 2020, an estimated $623K.
  • Kennedy Capital Management first reported a position in CytomX Therapeutics in Q2 2019 and held it in 4 quarters.
  • Kennedy Capital Management's CytomX Therapeutics position peaked at $847K in Q2 2019.
  • 134 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2020.

Based on Kennedy Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.